Mandate

VINGE ADVISES PANDOX IN RELATION TO ITS LISTING ON NASDAQ STOCKHOLM

June 18, 2015

Vinge advises Pandox Aktiebolag (publ) in relation to its listing on Nasdaq Stockholm. A prospectus was published on 8 June 2015 and the first day of trading on Nasdaq Stockholm was 18 June 2015. The price in the offering was set at SEK 106 per share, corresponding to a market value of all shares issued by Pandox of SEK 15,900 million. The total value of the offering amounts to SEK 6,360 million, assuming that the over-allotment option is exercised in full.

Pandox is a leading owner of hotel properties located in Northern Europe with focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio comprises 104 hotels in the upper medium- and upscale segment with a total of 21,969 hotel rooms across eight countries. The market value of Pandox’s property portfolio amounted to SEK 27 billion as of 31 March 2015.

Vinge’s team consisted mainly of Jesper Schönbeck, Charlotte Levin, Erik Sjöman, David Andersson, Joakim Hagberg, Adam Sandberg and Ludvig Berke. Marie Brommesson assisted in due diligence, including financing and property related matters, and Maria Schultzberg and Tora Hansjons assisted in tax related matters.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025